Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Inozyme Pharma Inc
(NQ:
INZY
)
5.400
+0.290 (+5.68%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Inozyme Pharma Inc
< Previous
1
2
3
4
5
Next >
Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting
October 06, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
6 Analysts Have This to Say About Inozyme Pharma
September 27, 2023
Via
Benzinga
Inozyme Pharma Posts Encouraging Data From Rare Calcification Disorders
September 26, 2023
Inozyme Pharma Inc (NASDAQ: INZY) announced interim safety, pharmacokinetic (PK), pharmacodynamic (PD), and exploratory efficacy data from its ongoing Phase 1/2 trials of INZ-701 in adults with
Via
Benzinga
Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)
September 26, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Analyst Expectations for Inozyme Pharma's Future
September 08, 2023
Via
Benzinga
4 Analysts Have This to Say About Inozyme Pharma
August 09, 2023
Via
Benzinga
Analyst Ratings for Inozyme Pharma
April 19, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
September 25, 2023
Via
Benzinga
Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023
September 20, 2023
Company to share interim data updates from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 06, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
August 08, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 03, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock
August 01, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock
July 27, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
July 27, 2023
Via
Benzinga
Inozyme Pharma, Inc. Announces Proposed Offering of Common Stock
July 27, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Outlines Plans For Pediatric Trial For ENPP1 Deficiency Treatment: Targets 2026 Commercial Launch For INZ-701
July 26, 2023
Following meetings with the FDA and the European Medicines Agency's Paediatric Committee, Inozyme Pharma Inc (NASDAQ: INZY) updated its global development strategy for INZ-701, a
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
July 26, 2023
Via
Benzinga
Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency
July 26, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Provide ENPP1 Deficiency Program Update on July 26, 2023
July 19, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701
June 27, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Present at the Jefferies Healthcare Conference
June 02, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Recap: Inozyme Pharma Q1 Earnings
May 09, 2023
Inozyme Pharma (NASDAQ:INZY) reported its Q1 earnings results on Tuesday, May 9, 2023 at 08:30 AM. Here's what investors need to know about the announcement. Earnings Inozyme Pharma beat estimated...
Via
Benzinga
Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights
May 09, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)
April 14, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Participate at the 22nd Annual Needham Virtual Healthcare Conference
April 11, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
April 06, 2023
Via
Benzinga
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Operations Officer
April 04, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.